Physician profile
Jacalyn M Bishop
NPI 1063579415
$9,254.07
in general payments reported to CMS, 2019-2025
32 companies · $769 in 2025
The $769 reported for 2025 was more than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,238 · 2020: $3,515 · 2021: $1,954 · 2022: $452 · 2023: $627 · 2024: $699 · 2025: $769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,096.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,095.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,508.01 | 2019-2025 | Lupron Depot |
| Tandem Diabetes Care, INC. | $2,179.32 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Novo Nordisk INC | $376.08 | 2019-2025 | Wegovy, Sogroya |
| Tolmar, INC. | $222.91 | 2023-2025 | Fensolvi |
| Pfizer INC. | $194.02 | 2019-2025 | |
| Medtronic Minimed, INC. | $181.97 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $154.69 | 2019-2025 | Strensiq |
| Boston Scientific Corporation | $138.30 | 2021-2024 | Wavewriter Alpha Prime 16 |
| Eton Pharmaceuticals, INC. | $133.95 | 2024-2025 | Alkindi, Increlex, Khindivi |
| Dexcom, INC. | $100.62 | 2021-2023 | Dexcom G6 Transmitter |
| Azurity Pharmaceuticals, INC. | $96.21 | 2023-2025 | Triptodur, Triptodur |
| Rhythm Pharmaceuticals, INC. | $94.65 | 2021-2025 | Imcivree, Imcivree |
| Ascendis Pharma Endocrinology INC | $76.00 | 2023-2025 | Skytrofa |
| Neurocrine Biosciences, INC. | $70.62 | 2025 | |
| Abbott Laboratories | $68.23 | 2020-2025 | Freestyle Libre 3 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $62.96 | 2020-2021 | |
| Medtronic, INC. | $60.30 | 2022-2023 | Minimed 780g |
| Ferring Pharmaceuticals INC. | $53.01 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $51.78 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $51.07 | 2020-2024 | Crysvita |
| Beta Bionics, INC. | $48.79 | 2024 | Ilet Bionic Pancreas |
| Tolmar Pharmaceuticals, INC. | $45.85 | 2022 | |
| Sandoz INC. | $40.19 | 2019 | |
| Arbor Pharmaceuticals, INC. | $37.63 | 2019 | |
| Insulet Corporation | $36.17 | 2024 | Omnipod |
| Biomarin Pharmaceutical INC. | $33.45 | 2022-2023 | Voxzogo 1.2mg |
| Lifescan, INC. | $27.00 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $26.48 | 2019 | |
| Mannkind Corporation | $25.88 | 2019-2022 | |
| Endo Pharmaceuticals INC. | $22.10 | 2022 | |
| Zealand Pharma US, INC. | $18.33 | 2022 | |
| Antares Pharma, INC. | $17.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacalyn Bishop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.